AIMD Stock Summary and Trading Ideas (Ainos | NASDAQ:AIMD)

Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.

Ainos trades on the NASDAQ stock market under the symbol AIMD.

As of January 27, 2025, AIMD stock price climbed to $0.81 with 1,357,190 million shares trading.

AIMD has a beta of 0.87, meaning it tends to be less sensitive to market movements. AIMD has a correlation of 0.01 to the broad based SPY ETF.

AIMD has a market cap of $11.41 million. This is considered a Sub-Micro Cap stock.

The top ETF exchange traded funds that AIMD belongs to (by Net Assets): VXF.

AIMD has underperformed the market in the last year with a return of -10.0%, while SPY returned +24.4%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in AIMD shares. However, AIMD has outperformed the market in the last 3 month and 2 week periods, returning +44.7% and +39.6%, while SPY returned +3.9% and +3.1%, respectively. This indicates AIMD has been having a stronger performance recently.

AIMD support price is $.70 and resistance is $.90 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AIMD shares will trade within this expected range on the day.